Back close
Admissions

BMPR2 mutation and clinical response to imatinib in a case of heritable pulmonary arterial hypertension

Publication Type : Journal Article

Publisher : Pulmonary Circulation

Source : Pulmonary Circulation, 2024 Jan 10;14(1):e12335. DOI: 10.1002/pul2.12335.

Url : https://pubmed.ncbi.nlm.nih.gov/38213946/

Keywords : Bmpr2 mutation, hereditary, imatinib, pulmonary hypertension

Campus : Kochi

School : School of Medicine

Department : Paediatric Cardiology

Year : 2024

Abstract : Bone morphogenetic protein receptor 2 (BMPR2) mutation is the most common gene mutation implicated in the pathogenesis of pulmonary arterial hypertension (PAH). We describe, for the first time, an excellent clinical response to tyrosine kinase inhibitor imatinib in a patient with heritable PAH from BMPR2 mutation.

Cite this Research Publication : Kumar S, Biswas L, Pushkaran AC, Kumar RK, "BMPR2 mutation and clinical response to imatinib in a case of heritable pulmonary arterial hypertension," Pulmonary Circulation, 2024 Jan 10;14(1):e12335. DOI: 10.1002/pul2.12335.

Admissions Apply Now